The results showed that IPI-IPM-associated genes were correlated with sensitivity to drugs targeting the Aurora kinase, DNA methyltransferase, histone acetyltransferase, FLT3, EGFR, and VEGFR signaling pathways, indicating that high-risk DLBCL patients may benefit from novel inhibitors targeting these signaling pathways. The gene discussed is EGFR; the disease is diffuse large B-cell lymphoma.